Compare Abbott Laboratories (ABT) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs State Street PDR S&P Retail ETF — how do they compare? Abbott Laboratories trades at $110.22 (market cap $187.95B), while State Street PDR S&P Retail ETF trades at $88.58. The key difference: Abbott Laboratories pays a 2.32% dividend while State Street PDR S&P Retail ETF pays none, and State Street PDR S&P Retail ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | XRT | |
|---|---|---|
Market Cap | $187.95B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $136.62 | $92.35 |
52-Week Low | $82.57 | $77.28 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
XRT trades at $88.81, down 1.96% today, with a bullish technical signal from moving averages and key indicators like ADX suggesting a strong trend. The ETF's valuation metrics are not available in the provided data, but recent news highlights retail sector focus amid mixed economic signals. A dividend of $0.19 is scheduled for June 2026, adding income potential.
The outlook for XRT is cautiously optimistic, driven by positive retail sales trends and potential Fed easing, but risks include consumer sentiment pressures and inflation. Analyst sentiment is mixed, with some downgrades citing macro headwinds, making it essential to monitor economic indicators for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
